Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. Eur Urol. 2022;82(2):201-211.

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Publisher Correction: Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(2):279.

Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordoñez A, Reina-Campos M, et al. The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022;39(6):110792.

Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2022;28(1):212.

Coan BG, Cesarman E, Acencio ML, de Oliveira DE. Latent Membrane Protein 1 (LMP1) from Epstein-Barr Virus (EBV) Strains M81 and B95.8 Modulate miRNA Expression When Expressed in Immortalized Human Nasopharyngeal Cells. Genes (Basel). 2022;13(2).

Zhao Z, Yang HS. Robust antibody response in children to acute COVID-19 infection and lasts for months. J Pediatr. 2022;240:310-313.

Feng H, Jiang B, Xing W, Sun J, Greenblatt MB, Zou W. Skeletal stem cells: origins, definitions, and functions in bone development and disease. Life Med. 2022;1(3):276-293.

Liu Y-, Illar GM, Amri RA, Canady BC, Rea B, Yatsenko SA, et al. Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis. Mod Pathol. 2022;35(5):625-631.

Cao XE, Ongagna-Yhombi SY, Wang R, Ren Y, Srinivasan B, Hayden JA, et al. A diagnostic platform for rapid, simultaneous quantification of procalcitonin and C-reactive protein in human serum. EBioMedicine. 2022;76:103867.

Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, et al. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion. 2022;62(7):1365-1376.